EQUITY RESEARCH MEMO

PolyAn

Generated 5/9/2026

Executive Summary

Conviction (model self-assessment)55/100

PolyAn is a German biotechnology company specializing in molecular surface engineering, founded in 1998 and headquartered in Berlin. The company develops and supplies functionalized microparticles, microarray substrates, and consumables for the diagnostics industry and life science research. Its core technology enables precise immobilization of biomolecules while reducing non-specific binding in assays, thereby improving assay sensitivity and reproducibility. PolyAn's products serve as critical components for in vitro diagnostics, proteomics, and other analytical platforms. While the company has not disclosed funding rounds or revenue, its long-standing presence and niche expertise position it as a reliable partner for OEMs and research institutions.

Upcoming Catalysts (preview)

  • Q4 2026Launch of next-generation microarray substrate with enhanced sensitivity70% success
  • Q3 2026Partnership with a major diagnostics OEM for microparticle supply60% success
  • TBDExpansion into CDMO services for molecular surface coating50% success
Locked sections
  • · Pipeline Analysis
  • · Competitive Landscape
  • · Catalyst Calendar (full 12-month)
  • · Bull Case
  • · Bear Case
  • · Counterfactual Scenarios
  • · Valuation Notes
  • · SEC Filing Highlights
  • · Insider Activity
  • · Literature Watch
  • · Patent Landscape
  • · Mechanism Cluster Map
  • · Audio Briefing (5 min)